Tovecimig with chemotherapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called tovecimig combined with a standard chemotherapy regimen (FOLFIRI) for people whose colorectal cancer has spread and has not been stopped by one prior treatment. The goal is to see if this combination is safe and effective as a second-line option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your colorectal cancer is advanced or has spread, and it has gotten worse after one previous round of treatment.
- You have had surgery to remove your primary colon or rectal tumor.
- Your tumor does not have a specific genetic feature called MSI-high (microsatellite instability-high).
- You are not taking blood thinners (like aspirin or ibuprofen) and do not have active bleeding or a history of a perforated bowel.
- You do not have uncontrolled heart disease or an active infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug called ivonescimab combined with chemotherapy for people with metastatic colorectal cancer that has not spread to the liver. The goal is to see if this combination can help control the cancer better than chemotherapy alone.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests whether adding the immunotherapy drug atezolizumab (Tecentriq) to standard chemotherapy (FOLFOXIRI) and bevacizumab (Avastin) is more effective as a first treatment for people with a specific type of metastatic colorectal cancer that has a high immune score and is mismatch repair proficient.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.